Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

• New Guardant Hereditary Cancer test offers germline testing to identify guideline-recommended genetic variants associated with cancer risk across 12+ tumor types
• Results help guide treatment decisions and enable healthcare providers to assess patient risk for secondary cancers

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that identifies genetic variants associated with cancer risk to help cancer care teams provide optimal patient care.

Germline genetic testing is recommended by medical practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention.¹ The testing analyzes inherited genetic variants, typically present in all the cells of the body, that may predispose an individual to certain risks or diagnoses, including hereditary cancers and other genetic conditions. The new Guardant Hereditary Cancer test is a blood-based germline panel test that identifies guideline-recommended genetic variants across 82 genes associated with an increased risk for more than 12 tumor types, including breast, colorectal, prostate, endometrial, renal and others.

“Introducing a best-in-class hereditary cancer test is another important step in achieving our mission to conquer cancer with data,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “It expands the portfolio we offer to support healthcare providers across the entire continuum of cancer care and allows them to access an even broader set of precision oncology tools through a single source. The germline testing will help them develop more informed personalized treatment plans for patients, reduce risk and improve outcomes.”

Physicians may order the Guardant Hereditary Cancer test for patients with a personal or family history of hereditary cancer for several reasons, such as guiding treatment or care decisions, assessing risk for secondary cancer development, and providing information that can help identify other family members who may be at increased risk for certain cancers. Discussion of risk-reducing strategies, enhanced screening, and referral to a specialist or genetic counseling is recommended.

The Guardant Hereditary Cancer test requires only a simple blood draw and can be ordered as a standalone test or added to Guardant360 liquid biopsy tests with no additional sample required. Results are available in two to three weeks.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

References

1. JAMA. 2023;330(1):43-51. doi:10.1001/jama.2023.9526.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520792476/en/